These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36662648)

  • 1. How should policymakers regulate the tetrahydrocannabinol content of cannabis products in a legal market?
    Hall W; Leung J; Carlini BH
    Addiction; 2023 Jun; 118(6):998-1003. PubMed ID: 36662648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public interest in ∆
    Leas EC; Nobles AL; Shi Y; Hendrickson E
    Int J Drug Policy; 2022 Mar; 101():103557. PubMed ID: 34952279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adult use of highly-potent Δ9-THC cannabis concentrate products by U.S. state cannabis legalization status, 2021.
    Hasin DS; Borodovsky J; Shmulewitz D; Walsh C; Struble CA; Livne O; Habib MI; Fink DS; Aharonovich E; Budney A
    Addict Behav; 2023 May; 140():107617. PubMed ID: 36736229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary on Allaf et al.: Comparing countries with different legal cannabis markets can inform on the impact of regulating product type and potency.
    Skumlien M; Craft S
    Addiction; 2023 Dec; 118(12):2275-2276. PubMed ID: 37544881
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of cannabis-infused edibles on public safety and regulation.
    Peralt A; Ke P; Castaneto MS
    J Forensic Sci; 2022 Nov; 67(6):2387-2393. PubMed ID: 36097671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the standard THC unit to regulate THC content in legal cannabis markets.
    Freeman TP; Lorenzetti V
    Addiction; 2023 Jun; 118(6):1007-1009. PubMed ID: 36987753
    [No Abstract]   [Full Text] [Related]  

  • 7. The virtues of bans on high-THC content cannabis products?
    Caulkins JP
    Addiction; 2023 Jun; 118(6):1004-1005. PubMed ID: 36709770
    [No Abstract]   [Full Text] [Related]  

  • 8. Rating the comparative efficacy of state-level cannabis policies on recreational cannabis markets in the United States.
    Blanchette JG; Pacula RL; Smart R; Lira MC; Boustead AE; Caulkins JP; Kilmer B; Kerr WC; Treffers R; Naimi TS
    Int J Drug Policy; 2022 Aug; 106():103744. PubMed ID: 35636068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potency levels of regulated cannabis products in Michigan 2021-2022.
    Glinn MA; Michaud GP
    J Forensic Sci; 2023 Nov; 68(6):1894-1905. PubMed ID: 37501559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative analysis of laws on recreational cannabis edibles between Canada and the United States of America.
    Goundar P; Macaulay T; Szafron M
    Int J Drug Policy; 2021 Aug; 94():103191. PubMed ID: 33756442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-reported THC content and associations with perceptions of feeling high among cannabis consumers.
    Lineham J; Wadsworth E; Hammond D
    Drug Alcohol Rev; 2023 Jul; 42(5):1142-1152. PubMed ID: 37062952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Synthetic cannabis': A dangerous misnomer.
    Darke S; Banister S; Farrell M; Duflou J; Lappin J
    Int J Drug Policy; 2021 Dec; 98():103396. PubMed ID: 34343944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol for a mobile laboratory study of co-administration of cannabis concentrates with a standard alcohol dose in humans.
    Karoly HC; Prince MA; Emery NN; Smith EE; Piercey CJ; Conner BT
    PLoS One; 2022; 17(11):e0277123. PubMed ID: 36327298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copycat and lookalike edible cannabis product packaging in the United States.
    Ompad DC; Snyder KM; Sandh S; Hagen D; Collier KJ; Goldmann E; Goodman MS; Tan ASL
    Drug Alcohol Depend; 2022 Jun; 235():109409. PubMed ID: 35459519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Price and product variation in Washington's recreational cannabis market.
    Davenport S
    Int J Drug Policy; 2021 May; 91():102547. PubMed ID: 31522966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncomfortably high: Testing reveals inflated THC potency on retail Cannabis labels.
    Schwabe AL; Johnson V; Harrelson J; McGlaughlin ME
    PLoS One; 2023; 18(4):e0282396. PubMed ID: 37043421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic cannabinoid poisonings and access to the legal cannabis market: findings from US national poison centre data 2016-2019.
    Klein TA; Dilley JA; Graves JM; Liebelt EL
    Clin Toxicol (Phila); 2022 Sep; 60(9):1024-1028. PubMed ID: 35942512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in the use of cannabis products in Canada and the USA, 2018 - 2020: Findings from the International Cannabis Policy Study.
    Hammond D; Goodman S; Wadsworth E; Freeman TP; Kilmer B; Schauer G; Pacula RL; Hall W
    Int J Drug Policy; 2022 Jul; 105():103716. PubMed ID: 35613480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of marijuana legalization on cannabis-related visits to the emergency department.
    Tolan NV; Terebo T; Chai PR; Erickson TB; Hayes BD; Uljon SN; Petrides AK; Demetriou CA; Melanson SEF
    Clin Toxicol (Phila); 2022 May; 60(5):585-595. PubMed ID: 34935567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Big data on a big new market: Insights from Washington State's legal cannabis market.
    Caulkins JP; Bao Y; Davenport S; Fahli I; Guo Y; Kinnard K; Najewicz M; Renaud L; Kilmer B
    Int J Drug Policy; 2018 Jul; 57():86-94. PubMed ID: 29709847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.